Form 4: Y-mAbs COO Equity Converted in Merger
Insider Transaction Report (Form 4)
Y-mAbs Therapeutics' SVP & COO, Joris Wilms, disposed of common stock and had equity awards converted to cash following the company's merger on September 16, 2025.
Summary
- Y-mAbs Therapeutics, Inc. (YMAB) completed a merger on September 16, 2025, becoming an indirect wholly-owned subsidiary of Perseus BidCo US, Inc., with Stark International Lux as the ultimate parent.
- SVP & Chief Operating Officer, Joris Wilms, disposed of 12,799 shares of common stock at the merger consideration price of $8.60 per share.
- 39,301 Restricted Stock Units (RSUs) held by Mr. Wilms were cancelled and converted into cash based on the $8.60 per share merger consideration.
- Employee Stock Options totaling 278,300 shares underlying were cancelled and converted into cash, calculated as the product of the number of shares and the excess of the $8.60 merger consideration over the option's exercise price.
- Options with an exercise price equal to or exceeding the $8.60 merger consideration were cancelled for no consideration.
Sentiment
Score: 5
Explanation: The filing is a factual report of a completed, pre-determined corporate action (merger) and its impact on an insider's equity holdings. It does not contain new information that would significantly alter sentiment beyond what was already known from the merger announcement.
Positives
- Reporting Person received cash for common stock, vested and unvested RSUs, and in-the-money employee stock options, providing liquidity.
Negatives
- Employee stock options with exercise prices equal to or exceeding the $8.60 merger consideration were cancelled for no value, resulting in a loss for those specific awards.
Risks
- Former shareholders of Y-mAbs Therapeutics, Inc. no longer participate in any potential future upside of the company as it is now a private entity.
- Holders of out-of-the-money stock options received no value for those awards during the merger.
Future Outlook
The filing reports a completed merger, resulting in Y-mAbs Therapeutics, Inc. becoming an indirect wholly-owned subsidiary. No forward-looking statements or guidance for the former public entity are provided.
Industry Context
This filing reflects the finalization of an acquisition in the biotechnology sector, where a publicly traded company is taken private. Such transactions are common in industries requiring significant capital investment and long development cycles, often driven by strategic alignment or valuation opportunities.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure | Y-mAbs Therapeutics, Inc. transitioned from a publicly traded company to an indirect wholly-owned subsidiary of Perseus BidCo US, Inc., fundamentally altering its governance and reporting structure. | 09/16/2025 | This change means the company is no longer subject to public company reporting requirements and its governance will be dictated by its new parent entity. |
Stakeholder Impact
- Shareholders: All public shareholders received $8.60 per share in cash, concluding their investment in the company.
- Employees (with equity awards): Employees like the Reporting Person received cash for their in-the-money stock and equity awards, while out-of-the-money options were cancelled without value.
Next Steps
- Y-mAbs Therapeutics, Inc. will continue operations as an indirect wholly-owned subsidiary of Perseus BidCo US, Inc.
Key Dates
| Date | Description |
|---|---|
| 08/04/2025 | Date of the Agreement and Plan of Merger. |
| 09/16/2025 | Date Purchaser completed a tender offer for shares and merged with Y-mAbs Therapeutics, Inc. (Effective Time of Merger). |
| 09/18/2025 | Date the Form 4 was signed by the Reporting Person's Attorney-in-Fact. |
| 08/22/2026 | Expiration date for a tranche of employee stock options with an exercise price of $4.38. |
| 12/05/2027 | Expiration date for a tranche of employee stock options with an exercise price of $9.35. |
| 12/11/2028 | Expiration date for a tranche of employee stock options with an exercise price of $21.97. |
| 12/10/2029 | Expiration date for a tranche of employee stock options with an exercise price of $33.74. |
| 12/15/2030 | Expiration date for a tranche of employee stock options with an exercise price of $53.88. |
| 12/14/2031 | Expiration date for a tranche of employee stock options with an exercise price of $15.73. |
| 04/26/2032 | Expiration date for a tranche of employee stock options with an exercise price of $9.51. |
| 01/17/2033 | Expiration date for a tranche of employee stock options with an exercise price of $4.70. |
| 01/26/2033 | Expiration date for a tranche of employee stock options with an exercise price of $4.55. |
| 01/18/2034 | Expiration date for a tranche of employee stock options with an exercise price of $9.83. |
| 01/17/2035 | Expiration date for a tranche of employee stock options with an exercise price of $6.16. |
Keywords
Y-mAbs Therapeutics, YMAB, Merger, Tender Offer, Form 4, Insider Transaction, Stock Options, RSU, Beneficial Ownership, Corporate Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.